Global Gastroesophageal Reflux Disease Therapeutics Market Insights Forecasts to 2033

• The Global Gastroesophageal Reflux Disease Therapeutics Market Size was Valued at USD 4.89 Billion in 2023
• The Market Size is Growing at a CAGR of 2.02% from 2023 to 2033
• The Worldwide Gastroesophageal Reflux Disease Therapeutics Market Size is Expected to Reach USD 5.97 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Gastroesophageal Reflux Disease Therapeutics Market Size is Anticipated to Exceed USD 5.97 Billion by 2033, Growing at a CAGR of 2.02% from 2023 to 2033.

Market Overview

Gastroesophageal reflux (GERD) is a chronic disease characterized by the inability of the lower esophageal sphincter muscle valve to close properly which leads to the reflux of stomach contents back to the esophagus. This backwash of stomach acid irritates the lower esophagus lining and primarily causes heartburn along with other symptoms such as dry and wheezing cough, asthma, recurrent pneumonia, and vomiting. Some foods that trigger GERD include coffee, citrus fruits and juices, tomatoes & processed tomato-based products, and carbonated beverages. These foods relax the lower esophageal sphincter, which is stimulated by the high levels of acid in citrus fruits and juices that cause stomach distension, leading to acid reflux. By keeping a food diary, an individual can identify food triggers allowing them to make necessary changes to one’s diet which reduces discomfort and improves overall health. As per the data provided by the National Institutes of Health GERD is one of the most often diagnosed digestive illnesses in the United States, with a frequency of 20% that causes a considerable economic burden in direct and indirect expenditures and negatively affects the quality of life.

Report Coverage

This research report categorizes the market for the global gastroesophageal reflux disease therapeutics market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global gastroesophageal reflux disease therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global gastroesophageal reflux disease therapeutics market.

Driving Factors

Treatment of gastroesophageal reflux disease (GERD) including proton pump inhibitors (PPIs), H2 receptor antagonists, and antacids can effectively treat and reduce the symptoms of this chronic disease. These treatments reduce the production of stomach acid, relieving severe symptoms such as heartburn and acid reflux. They also control acid levels, preventing GERD-related complications such as esophagitis, ulcers, and Barrett's esophagus which leads to esophageal cancer. In addition, GERD treatment improves patients’ quality of life, allowing them to consume a wider variety of foods and promote better sleep. These factors are significantly driving the market growth.

Restraining Factors

Proton pump inhibitors (PPIs) and H2 receptor antagonists can cause nutrient deficiencies, increasing the risk of osteoporosis, anemia, and other health issues. Some patients may experience side effects like headaches, diarrhea, or constipation. Long-term use of PPIs is also associated with an increased risk of certain infections and possibly kidney disease. Some patients experience side effects such as headaches, nausea, and vomiting. Treatment for GERD can address the symptoms but not the underlying cause, triggering symptoms to recur. These side effects are negatively affecting the gastroesophageal reflux disease therapeutics market.

Market Segmentation

The global gastroesophageal reflux disease therapeutics market share is classified into route of administration, drug type, and distribution channel

• The oral route segment is expected to hold the largest share of the global gastroesophageal reflux disease therapeutics market during the forecast period.   

Based on the route of administration, the global gastroesophageal reflux disease therapeutics market is divided into parental route and oral route. Among these, the oral route segment is expected to hold the largest share of the global gastroesophageal reflux disease therapeutics market during the forecast period. Oral medications like PPIs, H2 receptor antagonists, and antacids are the most commonly prescribed treatments for GERD due to their convenience, ease of administration, and effectiveness in managing symptoms. Patients prefer this mode of drug administration due to their long-term accessibility and practicality. The increasing availability of over-the-counter oral treatments for mild to moderate GERD is further driving the growth of this segment, which is expected to further drive the market for oral GERD treatments

• The proton pump inhibitors segment is expected to grow at the fastest CAGR in the global gastroesophageal reflux disease therapeutics market during the forecast period.   

Based on the drug type, the global gastroesophageal reflux disease therapeutics market is divided into H2 receptor blockers, proton pump inhibitors, antacids, and pro-kinetic agents. Among these, the proton pump inhibitors segment is expected to grow at the fastest CAGR in the global gastroesophageal reflux disease therapeutics market during the forecast period. PPIs are highly effective medications for reducing stomach acid production and managing GERD. They provide prolonged acid suppression, treat esophagitis, and prevent complications. The rising incidences of GERD complications are driving the demand for these therapeutic agents, leading to significant growth in the PPI segment in the coming years

• The online segment is expected to grow at the fastest CAGR in the global gastroesophageal reflux disease therapeutics market during the forecast period.   

Based on the distribution channel, the global gastroesophageal reflux disease therapeutics market is divided into retail, online, and hospital. Among these, the online segment is expected to grow at the fastest CAGR in the global gastroesophageal reflux disease therapeutics market during the forecast period. The online GERD treatment market is growing exponentially due to the increasing adoption of e-commerce and convenience offerings for consumers. The use of digital healthcare and online pharmacies is on the rise with the trend of self-medication and over-the-counter online treatments. Also, the COVID-19 pandemic has further boosted online shopping for healthcare products reflecting a continuous trend.

Regional Segment Analysis of the Global Gastroesophageal Reflux Disease Therapeutics Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global gastroesophageal reflux disease therapeutics market over the predicted timeframe.

North America is anticipated to hold the largest share of the global gastroesophageal reflux disease therapeutics market over the predicted timeframe. North America's GERD market is dominated by its widespread occurrence in individuals due to lifestyle factors like diet, obesity, and stress. The region's well-established infrastructure and significant healthcare spending support GERD therapeutics' widespread availability and consumption. Leading pharmaceutical companies in North America are actively researching and developing advanced treatments. The region's large population base and growing awareness of GERD and its symptoms contribute to its leading position in the GERD therapeutics market.

Asia Pacific is expected to grow at the fastest pace in the global gastroesophageal reflux disease therapeutics market during the forecast period. The region is experiencing significant growth in the GERD therapeutics market due to changing dietary habits, obesity, and urbanization. The expanding middle-class population and improved healthcare infrastructure are also contributing to increased access to medical care and pharmaceuticals. The growing awareness of GERD and treatment options, coupled with increased investments by pharmaceutical companies, make the region a prime market for significant growth in the coming years.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global Gastroesophageal Reflux Disease Therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Merck & Co., Inc.
• Johnson & Johnson
• Sanofi
• Dr. Reddy's Laboratories
• Mylan N.V.
• Pfizer Inc.
• Abbott Laboratories
• Boehringer Ingelheim GmbH
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company
• Bayer AG
• Eisai Co., Ltd.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2024, Phathom Pharmaceuticals received FDA approval for VOQUEZNA 10 mg tablets, a treatment for heartburn associated with Non-Erosive Gastroesophageal Reflux Disease in adults.

• In May 2024, Onconic Therapeutics, a prominent Korean biotechnology company, received approval from the Ministry of Food and Drug Safety for treating erosive gastroesophageal reflux disease in adults.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global gastroesophageal reflux disease therapeutics market based on the below-mentioned segments: 

Global Gastroesophageal Reflux Disease Therapeutics Market, By Route of Administration

• Parental Route
• Oral Route

Global Gastroesophageal Reflux Disease Therapeutics Market, By Drug Type

• H2 Receptor Blockers
• Proton Pump Inhibitors
• Antacids
• Pro-Kinetic Agents

Global Gastroesophageal Reflux Disease Therapeutics Market, By Distribution Channel

• Retail
• Online
• Hospital

Global Gastroesophageal Reflux Disease Therapeutics Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa